Medical Device Developments’ Post

CG BIO, a leading medical device company, announced that significant clinical results demonstrating a 100% interbody fusion success rate at 52 weeks for its innovative bone substitutes "Novosis and Excelos Inject" in the spine surgery have been published in "Journal of Clinical Medicine". The study, led by Prof. Jae-Hwan Cho of Asan Medical Center in Seoul and Prof. Ji-Won Kwon of Severance Hospital in Gangnam, investigated the effectiveness of Novosis in transforaminal lumbar interbody fusion (TLIF) surgery. The product, which contains human recombinant bone morphogenetic protein-2 (rhBMP-2), was shown to significantly increase fusion rates, which is critical to the success of lumbar surgery. We expect that this result will have a positive impact not only on patients but also on the medical environment and society, and we are one step closer to successfully entering the U.S. market, especially since it is a preliminary results of a product similar in composition to Novosis Putty, which is about to enter the U.S. market, the largest market in the world. Ref. 1. https://lnkd.in/gjUwh7bt Ref. 2. https://lnkd.in/gRvE5DjK #BMP2 #NOVOSIS #NOVOSISPUTTY #BDD #FDA #GSC2024 #CGBIO #Global

CG BIO, a headquarter of CG MedTech, announced that significant clinical results demonstrating a 100% interbody fusion success rate at 52 weeks for its innovative bone substitutes "Novosis and Excelos Inject" in the spine surgery have been published in "Journal of Clinical Medicine". The study, led by Prof. Jae-Hwan Cho of Asan Medical Center in Seoul and Prof. Ji-Won Kwon of Severance Hospital in Gangnam, investigated the effectiveness of Novosis in transforaminal lumbar interbody fusion (TLIF) surgery. The product, which contains human recombinant bone morphogenetic protein-2 (rhBMP-2), was shown to significantly increase fusion rates, which is critical to the success of lumbar surgery. We expect that this result will have a positive impact not only on patients but also on the medical environment and society, and we are one step closer to successfully entering the U.S. market, especially since it is a preliminary results of a product similar in composition to Novosis Putty, which is about to enter the U.S. market. Ref. 1. https://lnkd.in/gjUwh7bt Ref. 2. https://lnkd.in/gRvE5DjK #BMP2 #NOVOSIS #NOVOSISPUTTY #BDD #FDA #GSC2024 #CGMEDTECH #CGBIO

We Don’t Copy, We Innovate to Transform Patient Care. Inspired by the teachings of Dr. Henry Bohlman, we’ve developed the ACIFT Solofuse system to advance outpatient cervical fusion. This innovative design ensures precise implant placement, reducing radiation exposure and blood loss, while enabling faster recovery. Let’s continue driving innovation in spine surgery with a focus on improving safety and outcomes. See you at the Cervical Spine Research Society (CSRS) today at Booth #201, where we’re showcasing our fusion solutions and AxioMed motion-preserving total disc replacement systems. To Learn More. www.KICVentures.com www.NANISX.com NANISX KIC Ventures FacetFuse Sacrix NanoFUSE Biologics Inspan Sagitechnology LESS Spine MISquito AxioMed This post is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.

Peripheral angiograms with intervention are essential diagnostic and therapeutic procedures for addressing limb conditions. Utilizing contrast dye and X-ray imaging, surgeons precisely identify blockages, employing techniques such as angioplasty and stent placement to reinstate proper blood circulation.

Breaking News: Pulse Biosciences Receives FDA 510(k) Clearance for CellFX® nsPFA™ Percutaneous Electrode System    Pulse Biosciences (Nasdaq: PLSE) is excited to announce the FDA 510(k) clearance of our CellFX nsPFA Percutaneous Electrode System, a significant advancement in the field of minimally invasive surgery. CellFX nsPFA technology introduces a revolutionary nonthermal approach to soft tissue ablation, offering elimination of cellular tissues through controlled, natural Regulated Cell Death (RCD) while preserving noncellular structures. This cutting-edge technology will allow physicians to improve patient care through safe, nonthermal minimally invasive procedures.   According to Dr. Ralph Tufano, our Scientific Advisory Board Chair for Head and Neck Surgery, "The CellFX nsPFA Percutaneous Electrode System represents a much needed and promising new minimally invasive nonthermal treatment option for patients. For physicians, the system offers intuitive usability, short procedure times and customizable energy delivery to treat a variety of patients requiring soft tissue ablation."   As we prepare to launch our training and commercialization programs, we are excited about the future possibilities this FDA clearance opens for minimally invasive surgery. Pulse Biosciences is at the forefront of redefining surgical standards, and we look forward to sharing further developments during our 2023 earnings call on Thursday, March 28, 2024.   Press Release Link: https://lnkd.in/gby-hg3n   #PulseBiosciences #CellFX #nsPFA #MedicalInnovation #HealthcareTechnology

 📣 New publication!!! 📢 I'm thrilled to announce that our team, led by Dr. José F. Alfonso, has just published a groundbreaking study in an special issue in the Journal of Clinical Medicine on a brand-new surgical technique: Pseudochamber-Protected Keratoplasty (PPK) using the Endo-K Pro® implant. ⬆ This innovative approach is designed for high-risk cases of penetrating keratoplasty, providing a safer, closed-system alternative for full-thickness corneal transplants. 👀 👁️✨ With a focus on improving graft survival and minimizing complications, the PPK technique using the Endo-K Pro® implant offers an exciting option for surgeons managing complex cases. 👁️✨Our results show promising outcomes, and we believe this advancement could transform the approach to corneal transplantation in high-risk patients. #Ophthalmology #CornealTransplantation #Innovation #endok #SurgicalTechniques #EyeHealth #Research #MedicalAdvances 👁️🗨️ Check out the full article and dive into the details of our findings: 👇 👇 👇

CATEH is proud to announce that, in the first operation of its kind in our region, surgeons at Croatia’s Dubrava University Hospital used a CATEH EVOPEEK 3D-printed implant to correct the severe and extensive damage that a benign tumor had caused to a patient’s skull. The size and geometry of the implant required presented particular challenges to both CATEH and the surgeons as can be seen from the video below. CATEH’s EVOPEEK technology augments its 3DmoldX product, which is used to create patient-specific implants from the PMMA polymer that surgeons and dentists have for decades relied on for this purpose. Both of CATEH’s technologies have important advantages over other implant-production methods. Both comply fully with MDR and are approved for use throughout the EU. CATEH is an EU company focused on developing additive technologies for producing custom-made medical devices for patients. CATEH has developed its EVOPEEK product using PEEK provided by Evonik. RTL DANAS 08. 10. 2024. #CATEH #PSI #peek #evopeek #evonik #implants #neurosurgery #cranioplasty #medicaldevices #medtech #medical #3dprinting #healthcare #HZZO #UniversityHospitalDubrava #innovations #additivemanufacturing #technology #medicine #reconstructivesurgery #personalhealthcare #surgicalpreplanning #patientspecificimplants #rapidprototyping #health #innovation #3d #cancerfighter #cancertherapy #cancersupport #cancerresearch #cancerpatients #cancercure #cancercare

🎥Video Abstract🎥 Laparoscopic medulla-sparing ovarian tissue biopsy for cryopreservation: Step-by-step surgical technique Full link 👇 https://lnkd.in/dgFG-geT

We are excited to announce that the first papers have been published in #BiophotonicsDiscovery! 🎉 Don't miss this study, led by an interdisciplinary team of researchers from the University of Arizona Biomedical Engineering Department. They explored a novel approach to detect electrothermal ureteral injuries, a common complication during pelvic surgery: optical coherence tomography endoscopy. Their results were significant when comparing the resulting images to histology (gold standard). Biophotonics Discovery Editor-in-Chief Darren Roblyer of Boston University remarks, “This study provides an important step towards protecting patients from ureteral injuries during pelvic surgery. OCT is label-free, safe for the patient, and can be integrated into a remarkably small-diameter endoscope, providing a potentially excellent means for detecting and ultimately preventing these unfortunate injuries.” Read more here: https://lnkd.in/gCFmJBDg

Our article provides the first snapshot of UK Corneal surgeons' views on DWEK/ DSO in FECD. DWEK/ DSO has potential as a surgical technique in selective cases, particularly with RHO kinase inhibitors. Optimal visual outcomes with DWEK/ DSO depend on careful patient selection, necessitating an evidence-based approach to define patient selection criteria.